Oct 2026· Pathology, Research and Practice· Vol 289, pp.
156717
· 0 citations· 135 references
Medicine
TL;DR
This review examines how genetic, transcriptional, metabolic, epigenetic, and immune heterogeneity influence viral entry, replication, dissemination, and therapeutic activity in glioma and compares established and emerging platforms.
Abstract
High-grade gliomas remain difficult to treat because of their infiltrative growth, cellular heterogeneity, and resistance to conventional therapies. Oncolytic viruses (OVs) offer a therapeutic approach that combines preferential viral replication in malignant cells with activation of antitumor immunity. However, heterogeneous receptor expression, intracellular antiviral defenses, limited intratumoral distribution, and central nervous system safety constraints complicate clinical translation. This review examines how genetic, transcriptional, metabolic, epigenetic, and immune heterogeneity influence viral entry, replication, dissemination, and therapeutic activity in glioma. We compare established and emerging platforms, including adenovirus, herpes simplex viruses, PVSRIPO, measles virus, vaccinia virus, and M1 alphavirus, while distinguishing preclinical findings from clinical evidence. We also discuss approaches to tumor selectivity, delivery, immune microenvironment remodeling, and combination checkpoint blockade. Clinical studies demonstrate feasibility and occasional durable responses, but most are small and uncontrolled, and early activity has not consistently translated into benefit in larger trials. Progress requires platform-specific biomarkers, representative experimental models, rigorous neurological safety assessment, and controlled clinical evaluation. Improving specificity must therefore be considered together with tumor coverage, immune function, and clinically meaningful outcomes.
Ovarian cancer remains the most lethal gynecological malignancy, and the limited durability of standard treatments has motivated the development of new therapeutic strategies. Oncolytic viruses selectively replicate within and lyse tumor cells, releasing tumor antigens and inflammatory signals that can convert an immun...
Qiu-Man Wang, Yu Sun, Ru-Xin Liu et al.· Frontiers in Immunology· 0 citations
Oncolytic virotherapy has emerged as a promising cancer treatment that combines selective tumor destruction with potent stimulation of antitumor immunity. Unlike conventional therapies, oncolytic viruses (OVs) preferentially infect and replicate within malignant cells while sparing normal tissues, leading to direct tum...
Esraa M. Halawa, Sherihan G. Abdelhamid, Mahmoud M. Elhefnawi· Clinical and Experimental Me...· 0 citations
Oncolytic virotherapy has evolved from a tumor-selective cytolytic strategy into a programmable immunotherapeutic platform that reshapes the tumor microenvironment (TME). Oncolytic viruses (OVs) selectively infect malignant cells, induce immunogenic cell death, release tumor antigens, and activate innate and adaptive i...
A. Atoom, J. Rizaev, D. Polatova et al.· Cancer Treatment and Researc...· 0 citations
Oncolytic viruses (OVs) are increasingly viewed not only as tumor-lysing agents but also as immunotherapeutic platforms capable of functioning as in situ cancer vaccines. By selectively infecting malignant cells, inducing immunogenic cell death, releasing tumor-associated antigens and danger signals, and activating inn...
Kamil Rogalski, Michał Iwaszko, Anna Kuraś et al.· Microorganisms· 0 citations
Glioblastoma (GBM), as the most lethal malignancy of the central nervous system, faces the dual constraints of the physical barrier of the blood-brain barrier (BBB) and a highly immunosuppressive microenvironment, rendering conventional immunotherapies largely ineffective. Oncolytic viruses (OVs), which possess a d...
Oncolytic viruses (OVs) can selectively lyse tumor cells and remodel the immunosuppressive tumor microenvironment. However, monotherapy is limited by low response rates, systemic delivery barriers and antiviral-mediated viral clearance. Combinatorial strategies with immune-checkpoint inhibitors, CAR-T cells, cancer vac...
Yi-Xuan Tao, Xue-Min Chen, Ao Ye et al.· Future Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.